Financials in millions USD. Fiscal year is February - January.
Breakdown
TTM
06/30/2025
06/30/2024
06/30/2023
06/30/2022
06/30/2021
Revenue
2
2
0
0
0
0
Revenue Growth (YoY)
--
--
--
--
--
--
Cost of Revenue
--
--
--
--
--
--
Gross Profit
--
--
--
--
--
--
Selling, General & Admin
4
4
2
0
0
0
Research & Development
2
2
3
0
0
0
Operating Expenses
7
7
6
1
1
0
Other Non Operating Income (Expenses)
0
0
0
0
0
0
Pretax Income
-5
-5
-6
-1
-1
0
Income Tax Expense
0
0
0
0
0
0
Net Income
-5
-5
-6
-1
-1
0
Net Income Growth
--
-17%
500%
0%
--
--
Shares Outstanding (Diluted)
181.31
167.25
139.42
134.42
134.42
134.42
Shares Change (YoY)
--
20%
4%
0%
0%
--
EPS (Diluted)
-0.03
-0.03
-0.04
-0.01
0
0
EPS Growth
--
-33%
362%
42%
2,433%
--
Free Cash Flow
--
--
-5
-1
0
0
Free Cash Flow Per Share
--
--
--
--
--
--
Gross Margin
--
--
--
--
--
--
Operating Margin
-250%
-250%
0%
0%
0%
0%
Profit Margin
-250%
-250%
0%
0%
0%
0%
Free Cash Flow Margin
--
--
0%
0%
0%
0%
EBITDA
-5
-5
--
--
--
--
EBITDA Margin
-250%
-250%
--
--
--
--
D&A For EBITDA
0
0
--
--
--
--
EBIT
-5
-5
-6
-1
-1
0
EBIT Margin
-250%
-250%
0%
0%
0%
0%
Effective Tax Rate
0%
0%
0%
0%
0%
0%
Follow-Up Questions
What are LTR Pharma Ltd's key financial statements?
What are the key financial ratios for LTPLF?
How is LTR Pharma Ltd's revenue broken down by segment or geography?
Is LTR Pharma Ltd profitable?
Does LTR Pharma Ltd have any liabilities?
How many outstanding shares for LTR Pharma Ltd?
Key Stats
Prev.Close
--
Open
--
Day's Range
-
52 week range
$0.27 - $0.27
Volume
--
Avg.Volume
136.0K
EPS (TTM)
--
Dividend yield
--
Market Cap
--
What is LTPLF?
LTR Pharma Ltd. is a clinical-stage biopharmaceutical company, which engages in the provision of improving men’s health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. The company is headquartered in Brisbane, Queensland. The company went IPO on 2023-12-11. The firm is developing and commercializing therapies that address significant unmet medical needs. The firm is focused on improving men’s health through clinical development and commercialization of nasal spray treatments for erectile dysfunction. Its lead products, SPONTAN and ROXUS, are fast-acting intranasal sprays for the treatment of erectile dysfunction, enabling onset of action in 10 minutes or less. The firm is also advancing OROFLOW, a novel intranasal spray under development for the treatment of Oesophageal Motility Disorders (OMD) - a debilitating group of conditions affecting swallowing function. The firm's subsidiary is LTR Pharma Inc.